|Table of Contents|

Evalution of eosinophil level after treatment in predicting the efficacy and prognosis of patients with pancreatic cancer treated with anti-PD-1 antibody therapy(2 cases)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 13
Page:
2472-2475
Research Field:
Publishing date:

Info

Title:
Evalution of eosinophil level after treatment in predicting the efficacy and prognosis of patients with pancreatic cancer treated with anti-PD-1 antibody therapy(2 cases)
Author(s):
LU Changchang1DU Juan12MENG Fanyan2
1.The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine,Jiangsu Nanjing 210000,China;2.The Comprehensive Cancer Center of Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Jiangsu Nanjing 210000,China.
Keywords:
eosinophilsanti-PD-1 antibodymalignant tumorefficacy evaluation
PACS:
R735.9
DOI:
10.3969/j.issn.1672-4992.2023.13.018
Abstract:
Objective:To compare the eosinophil levels in advanced pancreatic cancer patients who benefited long-term from anti-PD-1 antibody therapy.Methods:To analyze the clinical data of two advanced pancreatic cancer patients who were treated with anti-PD-1 antibody in our hospital,and explore the relationship between eosinophil level and curative effect during treatment.Results:The tumors of the two patients shrunk significantly after immunotherapy with anti-PD-1 antibody and the time of progression free survival were significantly prolonged.The curative effect lasted for more than 25 months and 15 months respectively.During the treatment,it was found that the count and ratio of eosinophils in peripheral blood were significantly increased,especially after half a year of treatment,the increase in eosinophils is particularly significant and there were no immune-related adverse reactions.Conclusion:The level of eosinophils may be a potential evaluation index for the long-term benefit of anti-PD-1 antibody in the treatment of malignant tumors.A significant increase in eosinophils during treatment indicates a long time of immune benefit,and has a certain predictive value for clinical efficacy evaluation and prognosis.

References:

[1]XU L,ZOU C,ZHANG S,et al.Reshaping the systemic tumor immune environment(STIE) and tumor immune microenvironment(TIME) to enhance immunotherapy efficacy in solid tumors[J].J Hematol Oncol,2022,15(1):87.
[2]WEBER JS.Biomarkers for checkpoint inhibition[J].Am Soc Clin Oncol Educ Book,2017,37:205-209.
[3] ALVES A,DIAS M,CAMPAINHA S,et al.Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy[J].J Thorac Dis,2021,13(5):2716-2727.
[4] PONCIN A,ONESTI CE,JOSSE C,et al.Immunity and breast cancer:Focus on eosinophils[J].Biomedicines,2021,9(9):1087.
[5] MA Y,SHANG K,WU S,et al.The prognostic value of albumin-globulin ratio and eosinophil-neutrophil ratio in patients with advanced tumors undergoing treatment with PD-1/PD-L1 inhibitors[J].Nutr Cancer,2022,74(8):2815-2828.
[6]HWANG M,CANZONIERO JV,ROSNER S,et al.Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy[J].J Immunother Cancer,2022,10(6):e004688.
[7]AN HJ,CHON HJ,KIM C.Peripheral blood-based biomarkers for immune checkpoint inhibitors[J].Int J Mol Sci,2021,22(17):9414.
[8] LI F,DU X,LAN F,et al.Eosinophilic inflammation promotes CCL6-dependent metastatic tumor growth[J].Sci Adv,2021,7(22):eabb5943.
[9] TUCKER MD,BROWN LC,CHEN YW,et al.Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma[J].Biomark Res,2021,9(1):80.
[10] CEDERBERG RA,FRANKS SE,WADSWORTH BJ,et al.Eosinophils decrease pulmonary metastatic mammary tumor growth[J].Front Oncol,2022,12:841921.
[11] LIU Z,LIANG Y,TANG X,et al.Decrease in blood neutrophil-to-lymphocyte ratio indicates better survival after neoadjuvant chemotherapy in patients with advanced gastric cancer[J].Front Surg,2021,8:745748.
[12] DAI W,QIU X,LU C,et al.AGIG chemo-immunotherapy in patients with advanced pancreatic cancer:A single-arm,single-center,phase 2 study[J].Front Oncol,2021,11:693386.
[13]BAI X,DAI J,LI C,et al.Risk models for advanced melanoma patients under anti-PD-1 monotherapy-Ad hoc analyses of pooled data from two clinical trials[J].Front Oncol,2021,11:639085.
[14]DU J,LU C,MAO L,et al.PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC:A biomolecular exploratory,phase II trial[J].Cell Rep Med,2023:100972.
[15] CHENNAMADHAVUNI A,ABUSHAHIN L,JIN N,et al.Risk factors and biomarkers for immune-related adverse events:A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors[J].Front Immunol,2022,13:779691.
[16] HWANG M,CANZONIERO JV,ROSNER S,et al.Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy[J].Journal for ImmunoTherapy of Cancer,2022,10(6):e004688.
[17]MA Y,MA X,WANG J,et al.Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors:a retrospective analysis[J].World J Surg Oncol,2022,20(1):242.

Memo

Memo:
National Natural Science Foundation of China(No.82072926);国家自然科学基金(编号:82072926);江苏省自然科学基金(编号:BK20191114);湖北陈孝平科技发展基金会资助项目(编号:CXPJJH11900001-2019101 );江苏省南京市卫生科技发展专项资金资助项目(编号:YKK20080);
Last Update: 2023-05-31